-
BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week
13 Apr 2025 15:14 GMT
… treatment.
—Exelixis cancer drug Cabometyx expanded its FDA … Pharmaceuticals developed to treat allergic reactions to insect bites, medications … drug. The FDA approved it in 2000 for treating … muscular dystrophy gene therapy Elevidys, the pharmaceutical …
-
SNP Health Secretary slammed for failing to respond to muscular dystrophy families
13 Apr 2025 03:41 GMT
… children with muscular dystrophy access a new life extending drug. The … for the treatment which slows the progress of Duchenne muscular dystrophy (DMD … changing, safe and free medication is being withheld from … '.
We also treat our community members to …
-
Next-Gen Gene Editing for Muscular Dystrophy: Exploring the ARCUS Approach
10 Apr 2025 10:01 GMT
… conditions.
At the 2025 Muscular Dystrophy Association (MDA) Clinical … , ARCUS, as a treatment for Duchenne muscular dystrophy (DMD). Following adeno … treating DMD patients to learn what a successful trial … say exactly what our trial will look like, but …
-
Eteplirsen Treatment Linked to Slower Cardiac Decline in DMD
11 Apr 2025 22:44 GMT
… was the first drug approved to treat patients with DMD based … approval to first drug for Duchenne muscular dystrophy. News release. FDA. September 19, … #47;press-announcements/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy
-
Sarcomatrix Renews United States Orphan Drug Designation for LAMA2-Related Muscular Dystrophy Program
09 Apr 2025 23:55 GMT
… the U.S. Food and Drug Administration (FDA) for its Laminin-111 … disease currently has no approved treatments.
The renewed designation reinforces Sarcomatrix … Laminin-111’s potential to treat Duchenne muscular dystrophy and other neuromuscular disorders …
-
Translating Oculopharyngeal Muscular Dystrophy Research Into Clinical Application: Matthew Wicklund, MD
09 Apr 2025 22:28 GMT
WATCH TIME: 4 minutes
"This is a very smart move—a combination strategy that addresses both the abnormal and normal protein balance could redefine therapy for OPMD."
Oculopharyngeal muscular dystrophy (OPMD) is a rare, late-onset genetic disorder …
-
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts?
11 Apr 2025 17:06 GMT
… . Their flagship product, Firdapse, treats Lambert-Eaton Myasthenic Syndrome (LEMS … , Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) succeeds through orphan drug exclusivity and … in March 2024 for treating Duchenne muscular dystrophy, is projected to deliver …
-
No, Democrats, Trump Didn’t Kill Drug Research — Here’s What Actually Happened at the NIH
09 Apr 2025 14:56 GMT
… Courtesy of Retail Pharmacy Magazine
Democrats are … affected certain mental health drug trials and overdose … advancing treatments for rare diseases such as Duchenne muscular dystrophy, spinal … treatments can generate enormous profits.
While life-saving drugs …
-
Jailed shoplifter with over 180 previous offences vows to change his ways
13 Apr 2025 07:11 GMT
… , Smart received burgled prescription medication belonging to Jhoots Pharmacy, in Sandown.
Read … fund his addiction, suffers with muscular dystrophy, and every day he spent … he didn’t receive the medication he needed while in jail …
-
Amylyx Begins Phase 1 LUMINA Study of CAPN2-Targeting Agent for ALS
12 Apr 2025 19:45 GMT
… Next-Gen Gene Editing for Muscular Dystrophy: Exploring the ARCUS Approach … prior hypersensitivity to the study drug, or a history of … approved by the FDA as a treatment for ALS but … Pharmaceuticals announces topline results from global phase 3 PHOENIX trial …